Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Sodium oxybate for narcolepsy.

Martin B Scharf1

  • 1The Center for Research in Sleep Disorders, 1275 Kemper Road Cincinnati, OH 45246-3901, USA. mscharf@tristatesleep.com

Expert Review of Neurotherapeutics
|August 9, 2006
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

The Effects of Milnacipran on Sleep Disturbance in Fibromyalgia: A Randomized, Double-Blind, Placebo-Controlled, Two-Way Crossover Study.

Journal of clinical sleep medicine : JCSM : official publication of the American Academy of Sleep Medicine·2015
Same author

Low-dose sublingual zolpidem tartrate is associated with dose-related improvement in sleep onset and duration in insomnia characterized by middle-of-the-night (MOTN) awakenings.

Sleep·2008
Same author

Efficacy and safety of as-needed, post bedtime dosing with indiplon in insomnia patients with chronic difficulty maintaining sleep.

Sleep·2008
Same author

Efficacy and tolerability of indiplon in transient insomnia.

Journal of clinical sleep medicine : JCSM : official publication of the American Academy of Sleep Medicine·2007
Same author

Long-term nightly treatment with indiplon in adults with primary insomnia: results of a double-blind, placebo-controlled, 3-month study.

Sleep·2007
Same author

Effects of synthetic conjugated estrogens A on sleep quality in postmenopausal women with nocturnal diaphoresis and/or hot flushes: a pilot study.

Fertility and sterility·2007
Same journal

An overview of the safety and efficacy of sphenopalatine ganglion stimulation for the treatment of chronic cluster headache.

Expert review of neurotherapeutics·2026
Same journal

Multiomics and proteomic insights into Alzheimer's disease biology in Down syndrome.

Expert review of neurotherapeutics·2026
Same journal

Remote deep brain stimulation programming in childhood dystonia: opportunities, challenges, and future directions.

Expert review of neurotherapeutics·2026
Same journal

The differential diagnosis of astrocytic neoplasms and its impact on treatment and prognosis.

Expert review of neurotherapeutics·2026
Same journal

Corticosteroids in withdrawal therapy following medication-overuse headache: a systematic review.

Expert review of neurotherapeutics·2026
Same journal

Clinical efficacy of lacosamide in neuropathic pain: a systematic review of randomized controlled trials.

Expert review of neurotherapeutics·2026
See all related articles

Sodium oxybate, or gamma-hydroxybutyric acid, is the only U.S. FDA-approved treatment for narcolepsy symptoms like cataplexy and excessive daytime sleepiness. It offers a unique therapeutic option addressing both core issues with fewer side effects than other common treatments.

Area of Science:

  • Neurology
  • Pharmacology

Background:

  • Narcolepsy is a chronic neurological disorder characterized by cataplexy and excessive daytime sleepiness.
  • Current treatments often include antidepressants and stimulants, which may have limitations and side effects.

Purpose of the Study:

  • To review the clinical trial data for sodium oxybate in narcolepsy treatment.
  • To discuss the role of sodium oxybate in the therapeutic landscape of narcolepsy.

Main Methods:

  • Review of existing clinical trial results.
  • Analysis of sodium oxybate's efficacy and safety profile.

Main Results:

  • Sodium oxybate is approved for cataplexy and excessive daytime sleepiness in narcolepsy.
  • It addresses both primary symptoms of narcolepsy, unlike many other treatments.

Related Experiment Videos

  • Proper use is associated with a lower likelihood of tolerance and side effects.

    • Conclusions:

    • Sodium oxybate represents a significant therapeutic advancement for narcolepsy management.
    • It provides a targeted treatment option for both cataplexy and excessive daytime sleepiness.
    • Its unique mechanism and side effect profile position it as a valuable tool in narcolepsy care.